Desmopressin for patients with spontaneous intracerebral haemorrhage taking antiplatelet drugs (DASH): a UK-based, phase 2, randomised, placebo-controlled, multicentre feasibility trial

BACKGROUND: The risk of death from spontaneous intracerebral haemorrhage is increased for people taking antiplatelet drugs. We aimed to assess the feasibility of randomising patients on antiplatelet drug therapy with spontaneous intracerebral haemorrhage to desmopressin or placebo to reduce the anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Desborough, Michael J R, Al-Shahi Salman, Rustam, Stanworth, Simon J, Havard, Diane, Woodhouse, Lisa J, Craig, Jennifer, Krishnan, Kailash, Brennan, Paul M, Dineen, Robert A, Coats, Tim J, Hepburn, Trish, Bath, Philip M, Sprigg, Nikola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284719/
https://www.ncbi.nlm.nih.gov/pubmed/37353276
http://dx.doi.org/10.1016/S1474-4422(23)00157-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284719/
https://www.ncbi.nlm.nih.gov/pubmed/37353276
http://dx.doi.org/10.1016/S1474-4422(23)00157-6

Ejemplares similares